OABI Company Profile and Key Details

Q: Who are the executives of OABI?

Dr. Christel Iffland Ph.D.Senior Vice President of Antibody TechnologiesDr. Douglas S. Krafte Ph.D.Senior Vice President of Ion Channels/Transporters & Icagen Ion Channel Technology Site HeadMs. Donna Ventura CPASenior Vice President of Corporation ControllerMs. Marie-Cecile van de Lavoir D.V.M., Ph.D.Senior Vice President of Technical Operations & GeneticsMs. Cia McCaffreyVice President of People & TalentDr. Bill Harriman Ph.D.Senior Vice President of Antibody Discovery

NASDAQ : OABI

OmniAb

$1.39

0.03+2.21%

At Close 4:00 PM

61.59

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

OmniAb, Inc. (OABI) stock surged +0.72%, trading at $1.40 on NASDAQ, up from the previous close of $1.39. The stock opened at $1.39, fluctuating between $1.36 and $1.42 in the recent session.

Stock Snapshot

1.39

Prev. Close

159.34M

Market Cap

1.355

Day Low

-2.46

P/E Ratio

-0.57

EPS (TTM)

0.01

Cash Flow per Share

1.39

Open

113.82M

Number of Shares

1.42

Day High

70.05%

Free Float in %

3.14

Book Value

510.16K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 30, 2026	1.35	1.42	1.35	1.39	699.98K
Apr 29, 2026	1.40	1.41	1.36	1.36	527.46K
Apr 28, 2026	1.46	1.46	1.40	1.40	315.91K
Apr 27, 2026	1.45	1.50	1.43	1.44	343.21K
Apr 23, 2026	1.50	1.56	1.48	1.56	526.75K
Apr 22, 2026	1.50	1.58	1.48	1.50	1.52M
Apr 21, 2026	1.54	1.60	1.46	1.48	638.72K
Apr 20, 2026	1.61	1.63	1.50	1.55	887.28K
Apr 17, 2026	1.59	1.65	1.55	1.64	618.14K
Apr 16, 2026	1.48	1.57	1.44	1.56	735.2K
Apr 14, 2026	1.46	1.50	1.45	1.46	1.25M
Apr 13, 2026	1.47	1.48	1.43	1.46	782.9K
Apr 10, 2026	1.50	1.51	1.45	1.47	307.99K
Apr 09, 2026	1.50	1.57	1.49	1.50	248.49K
Apr 08, 2026	1.55	1.58	1.52	1.52	339.38K
Apr 07, 2026	1.53	1.56	1.46	1.51	372.77K
Apr 06, 2026	1.52	1.56	1.52	1.54	294.9K
Apr 02, 2026	1.58	1.58	1.52	1.54	272.96K
Apr 01, 2026	1.56	1.61	1.55	1.56	398.96K
Mar 31, 2026	1.58	1.58	1.54	1.57	285.31K

Contact Details

EmeryVille, CA 94608

United States

https://www.omniab.com 510 250 7800

About Company

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Stock Peers

ARGX

5.7+0.73%

argenx SE$781.72 REGN

20.7+3.02%

Regeneron Pharmaceuticals, Inc.$707.06 UTHR

0.28+0.05%

United Therapeutics Corporation$571.35 MDGL

-1.19-0.23%

Madrigal Pharmaceuticals, Inc.$517.39 VRTX

4.14+0.98%

Vertex Pharmaceuticals Incorporated$427.38 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-4.36-1.35%

Praxis Precision Medicines, Inc.$318.83 ALNY

8.3+2.76%

Alnylam Pharmaceuticals, Inc.$309.49 KRYS

2.31+0.89%

Krystal Biotech, Inc.$262.26 LGND

4.59+2.04%

Ligand Pharmaceuticals Incorporated$229.45

Company Overview

OmniAb, Inc. (NASDAQ:OABI) closed at $1.40 USD, gaining $0.01 (0.72%) from the previous close of $1.39. The stock is currently mid-range between its 52-week high and low $1.22 and $2.29. With a market capitalization of about $159.34 million, OmniAb, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.87). Key stats such as the average daily volume over the past year has been around 406.47 thousand shares, in line with its 52-week average. Headquartered in EmeryVille, CA, OmniAb, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Matthew W. Foehr, the company employs approximately 114 people and listed since September 30, 2021. OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 3.48%, SMA50 -3.26%, SMA200 3.03%). The stock’s 14-day RSI is 52.83 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -50.0% below its high and over 47.54% above its low. Average 10-day trading volume of 656.11 thousand shares is significantly above the 3-month average of 392.42 thousand, indicating heightened recent market interest.

Valuation Metrics

OmniAb, Inc. trades at a P/E ratio of -2.75, slightly below the S&P 500 average, with a price-to-sales ratio of 8.51 and a price-to-book ratio of 0.67 suggesting the stock is closer to book value. The P/FCF stands at -4.29, also below market averages.

Dividend & Fair Value

OmniAb, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.08. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 23.56% annually over the next five years. The latest quarter delivered EPS of -$0.11. The next quarter is forecast at -$0.09. Next year's EPS is expected at $1.17. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.00 to $3.00. The high target offers 115.83% upside. The low target suggests 115.83% downside. The mean target is $3.00. This offers 115.83% upside. OmniAb, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 04, 2026, missed forecasts by 37.5%. The prior quarter beat by 2.94%. Over the last six quarters, Apple has recorded several small beats. These include 14.29% in November 12, 2024.

Shareholding & Insider Activity

OmniAb, Inc. has 122.70 million shares outstanding. The public float is 84.85 million shares, elevated short interest at 7.90% of float. This equals 7.86 million shares. The short ratio is 14.02 days. Institutional investors hold 68.88% of the float. Insiders own 14.75%. Avista Acquisition Corp. holds 5.69 million shares, FOEHR MATTHEW W has 4.42 million shares and HIGGINS JOHN L has 2.93 million shares. Over the past six months, insider transactions show net selling. They sold 163.34 thousand shares across 12 transactions.

Financial & Profitability Overview

Over the trailing twelve months, OmniAb generated $34.16M in revenue, or $0.34 per share. Gross margin was 42.93%, operating margin -202.63%, and net profit margin -148.16%. Returns are negative, with ROA at -12.59% and ROE at -16.09%.
On valuation metrics, OmniAb trades at a P/E of -2.75, P/S of 8.51 and P/B of 0.67. The current ratio is 4.02 and quick ratio is 4.02. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 6.09 days. Debt-to-equity is 0.08, supported by a cash flow-to-debt ratio of -1.79.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, OmniAb posted revenue of $34.16M, down slightly from $59.08M in the prior quarter. Gross profit was $14.67M (margin 42.93%). Operating income was - $69.23M (margin -202.6%). Net income was- $50.62M (EPS - $0.51).
The company ended the quarter with $86.98M in cash and short-term investments, a total debt of $25.56M, and net debt of $9.20M. Total assets were $401.99M, with equity of $314.59M. Financials further reflected stability, with operating cash flow of $2.35M, free cash flow of $703.00K, and capital expenditures of - $1.64M.

Price Forecast & Outlook

Our AI price prediction model suggests that OmniAb, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.6%, with price expected at $1.34 by May 14, 2026, within a range of $1.27 to $1.41 3-Month Outlook: Projected rise of 79.86%, reaching $2.50 by July 29, 2026, with a range of $2.35 to $2.62. 1-Year Outlook: Projected gain of 269.06%, with price at $5.13 by April 30, 2027, within a range of $0.00 to $7.93.

Key Takeaways

OmniAb, Inc. (NASDAQ:OABI) shares are flat 2.7% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows OmniAb, Inc. trading at a premium to the broader market with a P/E of -2.75. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $8.55, suggesting 515.11% upside. Our AI forecast model points to short-term weakness (-3.6% over two weeks), a medium-term rise (79.86% over three months), and a longer-term gain (269.06% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current OmniAb, Inc. (OABI) stock price?

OmniAb, Inc. (NASDAQ: OABI) stock price is $1.40 in the last trading session. During the trading session, OABI stock reached the peak price of $1.42 while $1.36 was the lowest point it dropped to. The percentage change in OABI stock occurred in the recent session was 0.72% while the dollar amount for the price change in OABI stock was $0.01.

OABI's industry and sector of operation?

The NASDAQ listed OABI is part of Biotechnology industry that operates in the broader Healthcare sector. OmniAb, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of OABI?

Dr. Christel Iffland Ph.D.
Senior Vice President of Antibody Technologies
Dr. Douglas S. Krafte Ph.D.
Senior Vice President of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head
Ms. Donna Ventura CPA
Senior Vice President of Corporation Controller
Ms. Marie-Cecile van de Lavoir D.V.M., Ph.D.
Senior Vice President of Technical Operations & Genetics
Ms. Cia McCaffrey
Vice President of People & Talent
Dr. Bill Harriman Ph.D.
Senior Vice President of Antibody Discovery

How OABI did perform over past 52-week?

OABI's closing price is 13.93% higher than its 52-week low of $1.22 where as its distance from 52-week high of $2.30 is -39.43%.

How many employees does OABI have?

Number of OABI employees currently stands at 114.

Link for OABI official website?

Official Website of OABI is: https://www.omniab.com

How do I contact OABI?

OABI could be contacted at phone 510 250 7800 and can also be accessed through its website. OABI operates from 5980 Horton Street, EmeryVille, CA 94608, United States.

How many shares of OABI are traded daily?

OABI stock volume for the day was 510.16K shares. The average number of OABI shares traded daily for last 3 months was 406.47K.

What is the market cap of OABI currently?

The market value of OABI currently stands at $159.34M with its latest stock price at $1.40 and 113.82M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	114
Beta	0.85
Sales or Revenue	$34.16M
5Y Sales Change%	1.148%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

OABI Company Profile and Key Details

OmniAb

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways